Continuous Glucose Monitor (CGM) System chiefly consists of three major components, namely sensors, transmitters & receivers and Insulin Pumps. However, in conventional CGM systems, insulin pumps were optional, whereas they are an integral part of modern CGMs.
CGMs are more expensive than the conventional glucose monitoring systems. Technological innovation such as launch of artificial pancreas has taken diabetic care management to a next level. Recently, artificial pancrea got FDA approval. Thus, advancement in CGM systems makes possible early detection of hypoglycemia in an easy manner in comparison to infrequent point-of-care glucose meter measurements.
However, there are few limitations associated with the CGMs, as they do not replace finger prick method for accurate readings, they require skill and training in diabetes management and they are not yet covered by majority of the insurance providers.
The global continuous glucose monitoring (CGM) market is projected to reach $16,574 million by 2025 from 2016 value of $830 million growing at a CAGR of 33.5% during 2017 - 2025.

[b]Enquire About Report:[/b] https://www.progressivemarkets.com/enquiry-about-report/continuous-glucose-monitoring-cgm-market

Currently CGMs are chiefly used in home settings, diagnosed centers and hospitals. Main use of CGMs are for continuously monitoring the glucose level irrespective of the location and its usage is almost hassle free and hence is comfortably used in home settings.

Diagnostics center is another application area which is also gaining popularity due to increase in use in case studies so as to allow effective reporting methods of glucose levels. Currently, adoption of CGMs in the hospitals settings currently is not overwhelming however it is expected to gain a boost in next three to four years as it offers benefits in ICU medication such as:

• Detection of hypo-hyperglycemia
• Prediction of future glucose levels
• Instant feedback regarding treatment
• Improved patient comfort
• Assistance with insulin dose
• Less time

To manage diabetes effectively, real-time continuous glucose monitoring is of utmost importance across all age groups. Continuous glucose monitoring system (CGMS) enables effective managing blood glucose levels by providing trend data as well as alarms for the fluctuations in glucose levels. Adult population (>14years) segment was the highest contributor to the global continuous glucose monitoring systems market.

Incidences of diabetes in children are increasing every year. Europe has highest prevalence of diabetes with type-1 diabetes around 129,000 with 20,000 new cases per year. Approximately half of the patients diagnosed with type-1 diabetes are children every year. Countries such as the U.K., the Russian Federation and France have highest number of Type-1 diabetic children patients.
In low income regions such as Africa and some of the Asian countries children diagnosed with type-1 diabetes often goes undiagnosed. Even if they are diagnosed in time they lack means to obtain insulin, syringes and monitoring devices and as a result they die. This is the main reason why we get to see lesser number of children patients with diabetes in such regions.

Key Market Segments
• By Devices
• By Application
• By Age
• By Geography
• Key Audiences

[b]Get Discount On Purchasing of Report:[/b] https://www.progressivemarkets.com/get-discount/continuous-glucose-monitoring-cgm-market

[b]Company Profiles[/b] Included are
Medtronic Inc.
Dexcom Inc.
Novo Nordisk
Spring Health Solution Ltd
Roche
Animas Corporation
Ypsomed AG
Insulet Corporation

[b]Request Sample:[/b] https://www.progressivemarkets.com/request-sample/continuous-glucose-monitoring-cgm-market

[b]About Us[/b]
Progressive Markets is the answer to every possible business query. It is a market research and business consulting firm, headquartered in U.S. that aims to deliver conversant executive support to foster overall growth of an organization in its domain.
[b]Reach Us[/b]
5933 NE Win Sivers Drive,
#205, Portland, OR 97220,
United States.
Int'l: +1-971-202-1575
Toll Free: ++ 1-800-910-6452
Fax: +1-800-792-5285
[email protected]